SynteractHCR sends team to the American Lung Association's 'Fight for Air Climb'

stairs outside

Carlsbad, CA's SynteractHCR is deploying some new manpower in the fight against lung diseases. In addition to its clinical efforts to find better drugs for respiratory conditions, the company will send a team to raise money at the American Lung Association's "Fight for Air Climb."

The CRO team will climb the flights of stairs of a skyscraper on Sunday, April 10, to raise funds that'll support the American Lung Association's efforts. SynteractHCR conducts clinical research for drugs addressing related diseases such as asthma, cystic fibrosis, tuberculosis and lung cancer, its release said.

The fundraiser will have participants climb to the 32nd floor at One America Plaza in San Diego--657 steps--or do the course twice for a total of 1314 steps. Event organizers have developed an app to help participants raise money and grow involvement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

As of Tuesday, the event has raised 60% of its $100,000 goal. So far, the Celgene ($CELG) team has raised the most toward the goal with that team's participation at about $3,300.

Formed in 2013 with Synteract's buyout of Harrison Clinical Research, SynteractHCR has conducted Phase I to Phase IV studies in 60 countries in fields including oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory.

- here's the release
- read more on the event

Read more on

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.